In a significant triumph for global public health, the World Health Organization (WHO) announced that the prevalence of chronic hepatitis B virus (HBV) infections among children under five years of age has dropped to below 1%. This milestone represents a monumental shift from the "pre-vaccine era," where prevalence rates hovered around 5% during the 1980s and early 2000s. As the world marked World Hepatitis Day on July 28, 2020, this achievement serves as a testament to the power of international cooperation, immunization, and targeted health strategies.
However, as the global community celebrates this success, public health officials warn that the COVID-19 pandemic threatens to undo decades of progress. The path forward requires a renewed, aggressive commitment to preventing mother-to-child transmission, ensuring universal access to birth-dose vaccines, and maintaining the momentum of global health initiatives.
The Chronology of a Public Health Success Story
The decline of HBV in children is not a result of chance, but of a decades-long, systematic global effort to introduce and scale up vaccination programs.
The Pre-Vaccine Era (Pre-2000)
Prior to the widespread availability and administration of the hepatitis B vaccine, the virus was rampant. HBV is a silent killer, attacking the liver and, if left untreated, leading to chronic cirrhosis and liver cancer. Infants are particularly susceptible; approximately 90% of children infected within their first year of life develop chronic, lifelong infections. In the 1980s and 90s, the lack of universal immunization programs meant that thousands of children were infected at birth or in early childhood, leading to a massive burden of chronic disease that would manifest in adulthood.
The Rise of Immunization (2000–2019)
The turn of the millennium saw a concerted effort to change this trajectory. With the pivotal support of organizations like Gavi, the Vaccine Alliance, the global coverage of the three-dose hepatitis B vaccine series saw a dramatic climb. In 2000, global coverage was a meager 30%. By 2019, that figure had soared to 85%. This expansion of coverage effectively broke the chain of transmission for millions of children, preventing them from developing chronic infections that could have cut their lives short decades later.
The 2020 Milestone
The target to reach under 1% prevalence in children under five was a core goal of the Sustainable Development Goals (SDGs). By meeting this target, the global health community has successfully safeguarded a new generation from the life-altering consequences of liver disease.
Supporting Data: Where Progress Lags
While the global average is a cause for celebration, a closer look at the data reveals deep regional inequalities. The success of the three-dose regimen—now at 85% coverage—is a significant victory, but the most critical component of HBV prevention is the "birth dose."
WHO recommends that infants receive their first dose of the hepatitis B vaccine within 24 hours of birth. This timely administration is the most effective way to prevent mother-to-child transmission. Currently, global coverage for this birth dose stands at only 43%.
The disparity across regions is staggering:
- WHO Eastern Mediterranean Region: Birth dose coverage is 34%.
- WHO African Region: A concerning 6% coverage rate.
These gaps indicate that in many low- and middle-income countries, particularly in sub-Saharan Africa, newborns are still missing the most essential window of protection. Without the introduction and universal implementation of the birth dose, the goal of total elimination remains out of reach.
Official Responses: Leaders Call for Sustained Action
Dr. Tedros Adhanom Ghebreyesus, Director-General of the WHO, emphasized the moral imperative of this mission during the World Hepatitis Day commemorations. "No infant should grow up only to die of hepatitis B because they were not vaccinated," Dr. Tedros stated. "Today’s milestone means that we have dramatically reduced the number of cases of liver damage and liver cancer in future generations."
He further underscored the necessity of prioritizing maternal health even during global crises. "Preventing mother-to-child transmission of hepatitis B is the most important strategy for controlling the disease and saving lives. Even in the midst of the COVID-19 pandemic, we must ensure that mothers and newborns have access to life-saving services, including hepatitis B vaccinations."
Dr. Meg Doherty, Director of Global HIV, Hepatitis and STI Programmes at the WHO, highlighted the strategy of "triple elimination." This initiative focuses on the simultaneous elimination of mother-to-child transmission of HIV, syphilis, and hepatitis B. "Expanding access to a timely birth dose of the hepatitis B vaccine is the cornerstone of efforts to prevent mother-to-child transmission of HBV," Dr. Doherty noted. "For countries, especially in regions such as sub-Saharan Africa, where the birth dose of hepatitis B vaccine has not yet been introduced, it is a priority to assure that protection as early as possible."
The New Frontier: Testing and Antiviral Prophylaxis
Beyond the vaccine, the WHO is pushing for a more comprehensive approach to prenatal care. The organization now recommends the routine testing of all pregnant women for HBV, alongside tests for HIV and syphilis, as early as possible in the pregnancy.
When a pregnant woman tests positive for HBV, there is a risk of vertical transmission to the child during birth. To combat this, the WHO has issued new recommendations regarding antiviral prophylaxis. By providing expectant mothers with safe and effective antiviral medication, the risk of transmitting the virus to the newborn is significantly reduced. This approach acts as a vital safety net, especially in countries that have already achieved high vaccination coverage but still see breakthrough cases of infection.
Implications: The Shadow of COVID-19
The progress made in the last two decades faces a severe and immediate threat: the COVID-19 pandemic. The disruption of healthcare supply chains, the redirection of resources, and the fear of visiting clinics have led to a decline in routine immunization coverage globally.
The Modeling of Failure
A chilling study conducted by Imperial College London, in collaboration with the WHO, illustrates the potential consequences of complacency. Researchers modeled a "worst-case scenario" involving a one-year disruption to vaccination programs. The findings are sobering:
- A 60% disruption to the birth dose vaccine.
- A 20% disruption to childhood HBV immunization.
- A slow recovery period post-pandemic.
If these projections hold, the world could see an additional 5.3 million chronic HBV infections among children born between 2020 and 2030. Furthermore, these children would face an estimated 1 million additional HBV-related deaths later in their lives.
These figures underscore that every missed vaccination is not merely a logistical failure—it is a life-altering event for a child who will grow up with a chronic, potentially fatal condition. The pandemic has reminded the global health community that progress is fragile and that the "hepatitis-free future" is not guaranteed.
Conclusion: A Call for a Hepatitis-Free Future
Viral hepatitis remains a leading cause of death globally, with HBV and HCV (Hepatitis C) responsible for approximately 1.3 million deaths annually. While the decline of HBV in children under five is a landmark achievement, the work is far from complete.
The "triple elimination" initiative, combined with universal birth-dose vaccination and aggressive prenatal testing, provides a clear roadmap for the future. However, the success of these programs depends entirely on political will, sustained funding, and the resilience of primary healthcare systems.
As the world navigates the ongoing challenges of the post-pandemic era, the mission remains clear: ensure that no child is left vulnerable to a preventable disease. The milestones reached by 2020 must be treated not as the finish line, but as the foundation upon which a truly hepatitis-free future is built. Protecting the next generation from hepatitis B is an investment in human life that will yield dividends for decades to come, ensuring that the legacy of this generation is one of health, longevity, and eradicated disease.
About the Author
